Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Reexamination Certificate
2006-11-02
2011-10-18
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
C424S133100, C424S141100, C424S145100, C424S146100, C424S152100, C435S328000
Reexamination Certificate
active
08038993
ABSTRACT:
The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.
REFERENCES:
patent: 5693762 (1997-12-01), Queen et al.
patent: 7214775 (2007-05-01), Hanai et al.
patent: 7582296 (2009-09-01), Gilles et al.
patent: 2003/0219861 (2003-11-01), Rother et al.
patent: 2004/0254108 (2004-12-01), Ma et al.
patent: 2005/0232931 (2005-10-01), Ma et al.
patent: 2007/0015239 (2007-01-01), Bihoreau et al.
patent: 2009/0280116 (2009-11-01), Smith et al.
patent: 125 023 (1984-11-01), None
patent: 2 861 080 (2005-04-01), None
patent: WO-01/04269 (2001-01-01), None
patent: WO 02072832 (2002-09-01), None
patent: WO-2004/014955 (2004-02-01), None
patent: WO-2004/087757 (2004-10-01), None
patent: WO 2006138739 (2006-12-01), None
patent: WO 2007072866 (2007-06-01), None
Portolano et al., J Immunol. Feb. 1, 1993;150(3):880-7.
Rudikoff et al., Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Janeway et al., Immunobiology, 3rd edition, 1997, Garland Press, pp. 3:1-3:11.
William E. Paul, M.D., editor, Fundamental Immunology, 3d ed. Raven Press, 1993, p. 242.
Wood et al., “Expression of active human factor VIII from recombinant DNA clones”, Nature, vol. 312, pp. 330-337, (1984).
Gilles, JG et al., “Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction”, Blood, vol. 82, pp. 2452-2461, (1993).
Jarvis et al., “Induction of Human Factor VIII Inhibitors in Rats by Immunization with Human Recombinant Factor VIII: a Small Animal Model for Humans with High Responder Inhibitor Phenotype”, Thromb Haemost., vol. 72(2), pp. 318-325, (1996).
Saint Rémy, JM et al., “Anti-Idiotypic Antibodies: From Regulation to Therapy of Factor VIII Inhibbitors”, Vox Sang, 77 (suppl 1), pp. 21-24, (1999).
Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Proc. Natl. Acad. Sci USA, vol. 81, pp. 6851-6855, (1984).
Neuberger et al., “Recombinant antibodies possessing novel effector functions”, Nature 312, vol. 5995, pp. 604-608, (1985).
Jacquemin et al., “Mechanism and Kinetics of factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived From a Hemophilia A Patient With Inhibitor”, Blood, vol. 92, pp. 496-506, (1998).
Spiegel PC et al., “Structure of a factor VIII C2 domain-immunoglobulin G4κ Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII”, Blood, vol. 98, pp. 13-19, (2001).
Almagro, JC et al., “Structural differences between the repertoires of mouse and human germline genes and their evolutionary implications”, Immunogenetics, vol. 47, pp. 355-363, (1998).
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains”, Dev Comp. Immunmol., vol. 27, pp. 55-57, (2003).
Chothia and Lesk, “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol., vol. 196, pp. 901-917, (1987).
Little M. Et. Al: “Of mice and men: hybridoma and recombinant antibodies” Immunology Today, Elsevier Publications, Cambridge, GB, vol. 21, No. 8, Aug. 1, 2000, pp. 364-370.
Behrens Christian
De Romeuf Christophe
Gaucher Christine
Birch & Stewart Kolasch & Birch, LLP
LFB Biotechnologies
Szperka Michael
LandOfFree
Cytotoxic antibodies directed against antibodies inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic antibodies directed against antibodies inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic antibodies directed against antibodies inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4287030